Under the agreement, part of Medtronic’s reimbursement will be tied to clinical improvement measures to enhance care quality while lowering medical expenses. The outcomes-based model will affect Aetna members with type 1 and type 2 diabetes who transition to Medtronic’s insulin pump from multiple daily injections.
Some Aetna policyholders will transfer to one Medtronic insulin system, called the MiniMed 670G, which continuously self-adjusts insulin amounts based on a patient’s specific needs.
More articles on payer issues:
4 things to know about BCBSA’s 2016 community health investments
Aetna moving HQs to attract ‘younger people, innovation’
Cigna CEO: 2017 growth could involve Medicare Advantage deals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
